Elizabeth A. Garofalo - Mar 8, 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Mar 8, 2024
Transactions value $
-$95,617
Form type
4
Date filed
3/11/2024, 08:09 PM
Previous filing
Dec 6, 2023
Next filing
May 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $65K +3.5K $18.56* 3.5K Mar 8, 2024 Direct
transaction XENE Common Shares Tax liability -$65K -1.41K -40.23% $46.16 2.09K Mar 8, 2024 Direct F1
transaction XENE Common Shares Sale -$95.6K -2.09K -100% $45.69 0 Mar 8, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -3.5K -17.5% $0.00 16.5K Mar 8, 2024 Common Shares 20K $18.56 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on March 7, 2024 for purposes of net settlement calculations.
F2 One-third of the total shares subject to the Option vested on the one year anniversary of the grant date, one-third of the total shares subject to the Option vested on the two year anniversary of the grant date, and one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.